Full Breakdown
GLP-1 Medications Show Limited Impact on Cancer Risk, New Study Reveals
12/11/2025, 12:36:43 AM
Overview of the Study Findings
A recent study published in the *Annals of Internal Medicine* has cast doubt on the efficacy of GLP-1 medications, such as Ozempic and Zepbound, in reducing the risk of obesity-related cancers. Researchers analyzed data from 48 randomized trials involving 94,245 adults who were overweight, obese, or had type 2 diabetes. The study found that GLP-1 drugs had little to no effect on the risk of developing 13 types of cancers linked to obesity, including breast, thyroid, pancreatic, and kidney cancers.
Research Methodology
The study included over 51,000 participants who received GLP-1 medications and nearly 43,000 who were given placebos, with a median follow-up period of approximately 70 weeks. Co-author Dr. Cho-Han Chiang, now a medical oncology fellow at Northwell Health Cancer Institute, noted that while GLP-1 drugs can aid in weight loss—which hypothetically could reduce cancer risk—the findings indicate that these medications likely do not have a protective effect against cancer.
Limitations and Future Research
Dr. Chiang highlighted significant limitations in the study, including that none of the trials were specifically designed to measure cancer outcomes. Experts, including Dr. Kandace McGuire from Virginia Commonwealth University, emphasized the need for longer-term studies to fully understand the potential impact of GLP-1 drugs on cancer risk, particularly for slow-growing cancers. Current follow-up periods may not capture the long-term effects of these medications.
Official Statements & Responses
Dr. Bassel El-Rayes, deputy director of the O’Neal Comprehensive Cancer Center, expressed optimism about the study's findings, stating, “This study gives us more reassurance about using these drugs in the treatment of things like obesity and Type 2 diabetes.” However, he acknowledged that questions remain regarding potential long-term risks. Dr. Susan Wolver, director of the Medical Weight Loss Program at VCU Health, noted that patients typically seek GLP-1 medications for weight management and related health issues rather than cancer prevention.
Criticism & Opposition
Despite the study's findings, some experts caution against drawing definitive conclusions. Dr. El-Rayes pointed out that while the study is reassuring, it does not eliminate the possibility of a small increase in cancer risk that has yet to be identified. Additionally, the U.S. Food and Drug Administration warns that individuals with a personal or family history of rare thyroid cancers should avoid certain GLP-1 medications, although this warning is based on older rodent studies.
Verbatim Quotes
- “It’s not that GLP-1 does not reduce the risk of cancer; I don’t think we can make that conclusion from our study,” — Dr. Cho-Han Chiang, Medical Oncology Fellow
- “Nobody comes to me and says, ‘I’d like to go on some medication to reduce my cancer risk,’” — Dr. Susan Wolver, Director of Medical Weight Loss Program
- “I am relieved with the findings of this study that there does not appear to be any increased cancer signals,” — Dr. Susan Wolver, Director of Medical Weight Loss Program
Conclusion
The new research indicates that while GLP-1 medications may not increase cancer risk, their potential protective effects against cancer remain uncertain. Experts agree that further long-term studies are necessary to clarify the relationship between GLP-1 drugs and cancer risk, particularly for patients with a history of obesity-related conditions.
